New Multi-Center Study Shows equicenta® CTM, Ready-to-Use, Equine Umbilical Cord Allograft Outperforms Standard of Care in Returning Performance Horses to Work Equine Performance Labs (EPL), the team behind equicenta® CTM — announced the publication of a peer-reviewed, prospective, controlled clinical…
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the…
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Mirum Pharmaceuticals, Inc. a leading rare disease company, reported financial results for the second quarter 2026 and provided a business update. Mirum delivered another strong quarter, with continued…
Propel Software Launches Manufacturing Hub Providing Seamless and Standardized Integration with 12 ERP Platforms Propel, creator of the first product value management (PVM) platform to transform how manufacturers develop, launch, and service products, today announced its Summer 2026 release highlighted…
DXP Enterprises, Inc. Announces Acquisition of Mequipco Ltd. DXP Enterprises, Inc. announced that it has completed the acquisition of Mequipco Ltd. Founded in 1974, Mequipco is headquartered in Calgary, Alberta Canada and operates out of three locations servicing Western Canada including…
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering…
Neo7Bioscience & McCullough Foundation Expose 3.5-Year Spike Persistence, Cancer Genomic Integration & mRNA Gene Chaos — Personalized Precision Peptides Restore Critically Injured Patients Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence…
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases,…
Lantern Pharma Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and…
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline Glucotrack announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45…
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics…
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate Polpharma Biologics International AG announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License…